YUCAIPA, Calif., Aug. 24, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company will complete the final ISO Certification audit in December 2009 as a part of achieving ISO Certification for export sales in Europe, People's Republic of China, Canada, Japan and Australia.
On August 19, 2009, the company completed its second phase of ISO training for the required certification to market and sell the Oxyview and Oxyview Nasal Cannula in various countries outside the USA. The company was notified by The Emergo Group of a December 2009 ISO audit and completion to achieve the required ISO 13485 Certification.
"Ingen has invested $65,000 for ISO Certification to develop our staff, quality management systems and efficiency processes that represent the requirements that medical device manufacturers must incorporate into their management systems. Though based on ISO 9001, 13485 enforces emphasis on continual improvement and customer satisfaction. In its place is an emphasis on meeting regulatory as well as customer requirements, risk management and maintaining effective processes, namely the processes specific to the safe design, manufacture and distribution of medical devices. This is good for Ingen as it also complies with the new SEC auditing requirements and company stability," stated Thomas J. Neavitt, Chief Financial Officer of Ingen Technologies.
The company is evaluating distribution opportunities in all ISO rated countries, where it is expected to successfully sell Oxyview and the new Oxyview Nasal Cannula with a potential $200M in annual revenues. The company has denied several distribution inquiries from smaller based export distributors, and is negotiating with several larger medical distribution suppliers in China, Japan, Europe, Canada and Australia.
About Ingen Technologies/Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.